-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

Current Use of CAR T-Cells to Treat Multiple Myeloma

Program: Education Program
Session: How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies
Hematology Disease Topics & Pathways:
Research, clinical trials, Clinical Practice (Health Services and Quality), Clinical Research
Monday, December 11, 2023, 10:30 AM-11:45 AM

Sham Mailankody, MBBS

Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Disclosures: Mailankody: OncLive: Honoraria; Physician Education Resource: Honoraria; Optum Oncology: Consultancy; MJH Life Sciences: Honoraria; Janssen Oncology: Consultancy; Legend Biotech: Consultancy; Caribou Therapeutics: Research Funding; Takeda Oncology: Research Funding; Fate Therapeutics: Research Funding; Bristol Myers Squibb: Research Funding; Allogene Therapeutics: Research Funding; Janssen Oncology: Research Funding.

OffLabel Disclosure: Use of ide-cel and cilta-cel in earlier lines of therapy and discussion of CART cell therapies that are currently being evaluated in ongoing clinical trials but not approved by the FDA

See more of: How Do We Apply T-Cell Redirection Therapy for Multiple Myeloma? CAR T-Cells and Bispecific Antibodies
See more of: Education Program
<< Previous Presentation | Next Presentation >>